Loading...
XKRX052020
Market cap199mUSD
Aug 16, Last price  
6,270.00KRW
Name

STCube Inc

Chart & Performance

D1W1MN
XKRX:052020 chart
P/E
—
P/S
49.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.94%
Rev. gr., 5y
-12.05%
Revenues
5.83b
-7.54%
9,582,034,00012,471,345,00012,318,303,00017,644,044,0007,420,566,94011,230,833,0308,852,505,7305,483,597,8805,349,045,17015,263,722,1308,460,727,63011,073,434,41017,388,631,32010,121,806,0407,926,018,2506,302,336,6805,827,090,760
Net income
-24.50b
L+29.81%
-1,196,287,000-1,678,979,000-2,436,558,000208,831,000-4,640,266,000-1,500,708,000-10,626,267,000-9,845,736,310-5,502,637,650-6,267,169,000-16,453,531,000-10,706,792,000-21,237,084,000-18,930,791,360-22,009,713,690-18,873,096,440-24,499,001,250
CFO
-24.74b
L+53.80%
-333,236,000-1,263,517,0001,546,785,000-1,002,006,000-2,334,836,9702,137,262,920-6,860,265,120-2,687,838,810-4,274,150,9806,066,176,120-11,381,656,010-5,960,227,820-192,990,680-10,292,297,260-17,148,432,230-16,084,610,110-24,738,000,120

Profile

Stcube Inc is a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in Korea.
URL
http://www.stcube.com/
IPO date
Jul 05, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,827,091
-7.54%
6,302,337
-20.49%
7,926,018
-21.69%
Cost of revenue
24,417,719
18,689,539
20,750,286
Unusual Expense (Income)
NOPBT
(18,590,628)
(12,387,202)
(12,824,268)
NOPBT Margin
Operating Taxes
(18,782)
479,809
Tax Rate
NOPAT
(18,590,628)
(12,368,421)
(13,304,077)
Net income
(24,499,001)
29.81%
(18,873,096)
-14.25%
(22,009,714)
16.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,863,475
52,526,803
BB yield
-10.63%
Debt
Debt current
868,199
876,926
3,121,818
Long-term debt
2,657,899
2,963,955
1,973,806
Deferred revenue
Other long-term liabilities
5,476,870
4,446,418
3,669,538
Net debt
(17,598,286)
(19,103,721)
(10,347,012)
Cash flow
Cash from operating activities
(24,738,000)
(16,084,610)
(17,148,432)
CAPEX
(286,299)
(207,934)
(409,210)
Cash from investing activities
14,472,206
(26,611,983)
9,819,276
Cash from financing activities
8,040,162
50,440,099
(7,033,795)
FCF
(19,493,335)
(13,336,533)
(12,323,307)
Balance
Cash
34,762,268
51,862,313
19,125,233
Long term investments
(13,637,884)
(28,917,712)
(3,682,597)
Excess cash
20,833,029
22,629,485
15,046,335
Stockholders' equity
(80,019,451)
(56,184,134)
(43,383,872)
Invested Capital
122,567,557
113,770,664
67,023,308
ROIC
ROCE
EV
Common stock shares outstanding
50,207
34,447
35,928
Price
14,350.00
72.27%
8,330.00
-18.33%
Market cap
494,314,034
65.17%
299,276,308
-16.14%
EV
475,728,271
289,591,986
EBITDA
(17,531,522)
(11,202,257)
(11,697,328)
EV/EBITDA
Interest
96,179
483,824
651,337
Interest/NOPBT